

President William (Bill) Mixon called the meeting to order at 10 am. Board Members Ashley Duggins, Keith Vance, Andy Bowman, Wallace Nelson, Mischelle Corbin and Bill Mixon were in attendance. Also present were Executive Director Jay Campbell, Board Counsel Clint Pinyan, Director of Investigations Loretta Wiesner, Director of Inspections Krystal Stefanyk, Information Technology Administrator Antoine Pryor, Accounting Manager JP Brown, Board Investigator Maria Fabiano, Administrative Assistant Leslie Wilson and Director of Operations Kristin Moore. Present as visitors were Barry Glaz, Bunna Chea, and Amanda Fuller Moore. Members of the public also attended the meeting via teleconference.

Ethics Statement & Welcome

President Mixon read the Ethics Statement regarding conflicts of interest. No conflicts were noted by Board members.

Consideration of January 18, 2022 Meeting Minutes

Consideration of February 15, 2022 Meeting Minutes

Consideration of March 2, 2022 Meeting Minutes

It was moved by Ms. Corbin, seconded by Dr. Bowman, to approve the minutes. The motion passed with no dissenting votes.

Recognition of Pharmacists Continuously Licensed for 60 Years

The licensing staff, under Missy Betz' direction, has prepared certificates for North Carolina pharmacists continuously licensed for 60 years as of 2021. Unfortunately this year due to COVID, honorees are unable to attend and staff will mail the certificates to them. The Board wishes to recognize the following individuals and thank them for their years of service to our state.

Ben Philip Daughtry ~ UNC class of 1960, Licensed 3/6/1961
Hobson Ivan Gattis ~ Virginia Commonwealth class of 1959, Licensed 3/6/1961
Howard Robert Lutz ~ UNC class of 1960, Licensed 3/6/1961
Harold Griffin Usher ~ UNC class of 1960, Licensed 3/6/1961
Rufus Lynwood Daughtry ~ UNC class of 1961, Licensed 7/3/61
Robert Hunter Shearin ~ UNC class of 1960, Licensed 7/3/61

Consideration of Barry Glaz Reciprocity Application (*Pinyan*)

Barry Glaz has applied to reciprocate his New York license to practice pharmacy to North Carolina. In 2000, Mr. Glaz pleaded guilty in federal court to a felony count of conspiracy to defraud the Internal Revenue Service. Mr. Glaz assisted a business partner, Steven Geffen, with a scheme whereby Mr. Geffen, in violation of the federal Food Drug & Cosmetic Act, diverted prescription drug samples and sold them to various pharmacies, including pharmacies partly owned by Mr. Glaz. Mr. Glaz knew of the prescription drug sample scheme and knowingly dispensed prescription drug samples acquired by his pharmacies. Mr. Glaz filed fraudulent corporate tax returns on behalf of his company to disguise the fact that Mr. Geffen was receiving payments for the illegal sale of prescription drug samples.

After receiving testimony and evidence from Mr. Glaz, and receiving evidence from Board Counsel Clint Pinyan, the Board recessed for discussion. At the conclusion of the recess, the Board voted unanimously to deny Mr. Glaz' application to reciprocate his New York license to practice pharmacy to North Carolina.

The Board broke for lunch at 12:30 pm and resumed session at 1:15 pm.

Financial Report

Monthly Financial Report (*Brown*)

The members received the monthly financial report prior to this meeting. The members reviewed and had no questions.

Licensing Update

2022 Renewal Season (*Betz*)

Ms. Betz provided a briefing on the 2022 license/permit/registration renewal season and included a comparison with 2021 renewal season. Renewal has ended for all people (Pharmacists, Technicians, Dispensing Physicians, PAs, NPs, and CPPs). The facilities (Pharmacy and DME) may still reinstate during the month of March, with a late fee. Renewal trends are consistent with previous years.

Board Member Elections for Northern and Western District Seats (*Moore*)

Mr. Campbell congratulated Keith Vance of Lewisville for being elected by North Carolina pharmacists for a second term as the member from the Northern District, and Chris Sain of Hickory for being elected to a term as the member from the Western District. The Board certified the election results at its March 2, 2022 meeting.

Once commissioned by Governor Roy Cooper, Dr. Sain will take, and Dr. Vance will resume, office effective May 1, 2022. The Board and its staff wish them every success in their mission to protect the health and safety of North Carolina's citizens.

Mr. Campbell expressed appreciation to the other candidates for Board membership. From the Western District – Mike Anneken and Mike Long. From the Northern District – Rob Harrison, Joe Maki, and Josh McDuffie. Their commitment to public service is evident by their candidacy and the showing of support that each garnered during the election.

Investigative Report (*Stefanyk*)

Krystal Stefanyk, Director of Inspections, presented the investigations report and current caseload.

Mr. Campbell introduced Loretta Wiesner as the newly appointed Director of Investigations. Ms. Wiesner thanked Mr. Campbell for his kind words and said she was honored to serve the Board in this position.

Rulemaking (*Pinyan, Campbell*)

Proposed Amendments to Rules 21 NCAC 46.1503, .1612, .1613, & .1615,
Experience in Pharmacy and Pharmacy Internship

The comment period on the Board's proposed rule to create a uniform system through which the Board can document and verify both eligibility for pharmacy intern status and experiential hours acquired toward licensure closed on February 14, 2022. No comments were received on the proposed rule amendments. Dr. Bowman moved to adopt the rule amendments as proposed. Dr. Duggins seconded. The motion passed unanimously.

Proposed Amendments to Rules 21 NCAC 46.1606 & .1607, North Carolina-Specific
Education for Permit Applicants and Out-of-State Pharmacies

On February 14, 2022, the comment period ended on the Board's proposed rule to: (a) eliminate the requirement that pharmacist-manager of each permit applicant meet personally with Board staff prior to a grant and replacing it with an on-line educational module; and (b) update the Board's out-of-state permit rule. The Board received several comments on the proposed update of the Board's out-of-state permit rule. The PM Education Committee met on Tuesday, March 1, to thoroughly analyze the comments received. The Committee recommended adopting .1606 as published. For .1607, the Committee recommended a

number of non-substantial changes to the rule, which are detailed in a memo provided to all Board members.

Mr. Nelson moved to adopt the amendments to Rule .1606 as published, and the amendments to Rule .1607 with the non-substantial changes recommended by the PM Education Committee. Ms. Corbin seconded. The motion passed unanimously.

Proposed Adoption of New Rule 21 NCAC 46.2515, Remote Work by Pharmacy Personnel

On February 14, 2022, the comment period ended on the Board's proposed rule to permanently authorize pharmacy personnel employed by a pharmacy to perform pharmacy practice (other than any physical acts in the dispensing process) remotely with respect to drugs, devices, or medical equipment dispensed by the permitted pharmacy location by which they are employed. The Board received three comments on the proposed rule: CVS Health and Biologics by McKesson each support adoption of the rule as proposed. Andy Clark of Optum asked whether a "remote employee [could] generate labels and paperwork remotely that prints at the pharmacy, or must that work be done in the pharmacy's physical brick and mortar location?" Board staff responds that the "other physical acts in the dispensing process" limitation on remote work by employee pharmacy personnel does not prohibit offsite activities that generate paperwork and labels that will ultimately be applied to the prescription dispensed or conveyed to the patient at the pharmacy.

Dr. Bowman moved to adopt the proposed new rule as published. Ms. Corbin seconded. The motion passed unanimously.

Proposed Publication of Repeal of 21 NCAC 46.2403, Drugs and Devices To Be Dispensed By Health Department Nurses

N.C. General Statute 90-85.34A states the conditions under which a registered nurse at a local health department may dispense drugs. Among other things, the statute specifies that nurses may dispense drugs and devices contained in a formulary recommended by the North Carolina Department of Health and Human Services and approved by the Board of Pharmacy. Board rule .2403 lists the drugs and devices contained in the approved formulary. Under that rule, any change to the approved formulary requires the Board to undertake a rulemaking proceeding.

Amanda Fuller Moore of DHHS Division of Public Health came before the Board to ask for a repeal of current rule .2403. The statute prescribes the manner in which the local health department RN dispensing formulary is established. The statute does not require the Board's approval to occur by rulemaking. Rather, the Board may, as the statute contemplated, consider

DHHS requests to alter the formulary as an action item at a Board meeting, and may maintain the formulary on the Board's website. Managing the formulary under the statutory process is likely to be more efficient, timely, and flexible.

Mr. Wallace moved to publish a proposed repeal of rule .2403 for notice and comment. Ms. Corbin seconded. The motion passed unanimously.

Proposed Publication of Amendment to 21 NCAC 46.1317(2), Definition of
"Approved school or college of pharmacy"

On February 7, 2022, the Accreditation Council for Pharmacy Education (ACPE) announced a change in the terminology that will be used in ACPE's International Services Program. The change, effective, January 1, 2023, is that ACPE will now begin referring to credentials within its international program as "International-Accreditation", "International PreAccreditation", and "Provisional International-Accreditation." ACPE expressly disclaims any intention that this new terminology make graduates of foreign schools of pharmacy eligible for licensure in the United States (bypassing the Foreign Pharmacy Graduate Examination Equivalency program).

ACPE reports that is requiring the following:

- A disclaimer using wording specified by ACPE on the foreign school's website and other applicable media, publications, etc.
- All enrolled students must sign an acknowledgement that graduation from the program with International-Accreditation Status does not confer eligibility to graduates to apply directly to sit for the North American Pharmacist Licensure Examination (NAPLEX) for licensure in the US
- An agreement that schools with programs with [current] Certification Status will need to sign stating they will comply with the new Policies and Procedures before the status of the program is changed from "Certified" to "Internationally-Accredited" (or other status, as applicable); i.e., "grandfathering." Board of Pharmacy rule .1317(2) defines an "approved school or college of pharmacy" as "a school or college of pharmacy accredited by the American Council on Pharmaceutical Education."

Board staff recommends amending the Board's definition of "approved school or college of pharmacy" for two reasons: First, while ACPE's clear statement of distinction between its accreditation program for US-based pharmacy schools and its international-accreditation program for non-US-based pharmacy schools is appreciated, Rule .1317's simple reference to "accredited by" could lead to regulatory confusion. The rule should be amended to make clear that "accredited by" does not include ACPE "international-accreditation." Second, Rule .1317's incorrectly refers to ACPE by an old name.

Ms. Corbin moved to publish the proposed amendment for notice and comment. Dr. Bowman seconded. The motion passed unanimously.

Update: Amendments to 21 NCAC 46.1816

As reported on February 22, the amendments to Rule .1816 (centralized pharmacy services and expanded remote medication order processing services) cleared the Rules Review Commission. The amended rule has an effective date of March 1, 2022. Even so, some key implementation tasks remain. Board staff need to program a registration system for out-of-state pharmacists who are not licensed in North Carolina, but who intend to provide RMOE services to North Carolina pharmacies by obtaining an NABP Verify credential. NABP staff are implementing the NABP Verify credential application process. Board staff anticipates that both these steps will be completed by April 1, 2022. In the meantime, North Carolina pharmacies who have implemented RMOE systems under the Board's emergency services waiver may continue to use them.

To reassure pharmacies that have operated under the waiver that there will not be a gap between the shift from waiver-based services to rule-based services, Board staff recommends announcing that the rule-based system will not be enforced until June 1, 2022. That would give a 60-day bridge between the expected implementation of Board- and NABP-registration systems to get eligible RMOE pharmacists in other states Verify-credentialed (or seek NC licensure by reciprocity). It would also provide reassurance that even if the public health state of emergency is lifted (taking with it the Board's waiver authority), pharmacies may still have an orderly transition to the rules-based system.

It was the consensus of the Board to begin enforcing revised Rule .1816 on June 1, 2022.

Update: Comment Period for Proposed Permanent Rule 21 NCAC 46.2514, Administration of Long-Acting Injectables; Comment Period for Proposed New Rule 21 NCAC 46.1820, Code of Ethics; and Comment Period for Proposed Amendments to 21 NCAC 46.2507, Administration of Vaccines

The Board began each of these rulemakings after its January meeting. The public comment period is underway, and a public hearing scheduled for April 28. Board staff are monitoring for any comments.

The Board took a short break and reconvened at 2:30 pm.

Legislative Update

S.L. 2021-110 Implementation Update (Campbell)

The provisions of S.L. 2021-110 granting qualified “immunizing pharmacists” authority to initiate five classes of drug therapy became effective on February 1. Implementation of that authority, however, is dependent on the State Health Director issuing standing orders. Various stakeholders continue to collaborate with State Health Director Tilson to finalize these standing orders. Board staff anticipates their being issued in the near term.

The Board has approved funding for a required training course for pharmacists who wish to exercise the hormonal contraceptive authority in S.L. 2021-110. Once the standing order has been issued, NCAP will complete production of that training course and make it available to North Carolina pharmacists.

Once the standing orders are issued, the Joint Pharmacy/Medical Board Committee to Implement S.L. 2021-110 will convene to begin work on permanent protocols.

Committee Progress Reports

Telepharmacy Committee – *Vance, Bowman, Nelson* (members); *Campbell, Pinyan* (staff)

RMOE rulemaking has concluded. Committee is now turning to consideration of direct-to-patient dispensing technologies. Committee members visited Parata Systems in Durham on December 7, 2021. The Committee will reconvene on the Board’s April 19 workday to resume discussion.

Permit Meeting/Pharmacist Manager Education Committee – *Duggins, Vance* (members); *Betz, Watson, Kohler, Stefanyk* (staff).

Committee met on Tuesday, March 1 to consider comments on proposed amendments to Rule .1607 and make recommendations to the full Board. Production of the pharmacist-manager education module continues.

Intern Registration System Committee – *Vance, Bowman, Corbin* (members); *Betz, Campbell, Pinyan* (staff)

Notice and comment rulemaking underway to implement committee recommendations. Committee staff working on a registration application and discussing programming needs to implement.

Working Conditions Committee – *Duggins, Vance, Bowman* (members); *Campbell, Pinyan* (staff)

Dr. Duggins spoke as chairman of the committee. In partnership with NCAP, the Committee prepared a community pharmacy working conditions survey for pharmacists. The survey was posted and emailed to pharmacists on March 1. Dr. Bowman reported that there were 1049 surveys completed and 285 in progress.

Board staff have completed the content of a working conditions-specific complaint form for pharmacists' use reporting problems. ThoughtSpan is engaged in programming to integrate that form into our on-line systems.

Update on FDA MOU Litigation (*Campbell*)

When FDA issued the final version of the MOU last fall, several compounding pharmacies filed a lawsuit against FDA to try and block the MOU's implementation. In late September 2021, the federal district court for the District of Columbia ruled that the FDA's MOU is subject to the Regulatory Flexibility Act – a statute that, in certain instances, obligates a federal agency to certify that a proposed action will not impose material costs on small businesses or to conduct an analysis showing that the action chosen was better than more costly alternatives to accomplish the regulatory end. The district court disagreed and remanded the matter back to the FDA to perform the RFA certification or analysis within 60 days.

On February 23, 2022, FDA provided an update on the litigation and its plan going forward:

In October 2020, FDA was sued in the U.S. District Court for the District of Columbia regarding the MOU, and the Court remanded (returned) the MOU to FDA to either certify that it will not have a significant economic effect on small businesses or prepare a regulatory flexibility analysis. The agency intends to engage in notice-and-comment rulemaking to fully undertake this analysis and ensure a robust framework for these important public health protections regarding certain distributions of compounded human drugs. FDA intends to update the MOU based on the content of a final rule and announce a new opportunity for all states to consider and sign the MOU. The agency considers the MOU published in October 2020 to be suspended for the duration of the rulemaking process. This means that, during the rulemaking process, the agency will not enter into new agreements with states based on this MOU. FDA does not expect states that have signed the MOU to carry out the activities described in the MOU. FDA does not intend to enforce the statutory 5 percent limit on the distribution of compounded drugs out of the state in which they are compounded by compounders located in states that do not sign the MOU for the duration of the rulemaking process. FDA plans to provide updates, as appropriate, on the rulemaking and MOU. The MOU was developed in consultation with the National Association of

Boards of Pharmacy as described in section 503A of the Federal Food, Drug, and Cosmetic Act (FD&C Act) and was the product of more than 20 years of collaborative dialogue and stakeholder input. The MOU is a key public health protection in the law and is anticipated to help enhance communication and maximize federal and state resources for oversight of compounded drugs produced by traditional pharmacies. FDA is committed to implementing these important public health protections.

This update doesn't change the status quo in any way. If and when the MOU is again offered for state signature, the Board will discuss implementation.

NABP Annual Meeting, May 19-21, 2022, Phoenix AZ

Registration is open. Members asked to contact Ms. Wilson to register.

District 3 Meeting, August 7-10, 2022, Flowood, MS

The Board will be notified when registration is open.

MALTAGON Meeting, September 18-22, 2022, New Orleans, LA

Registration is also not open yet. Mr. Campbell just wanted the Board to be aware of the dates.

SEIs Due to Ethics Commission by April 15, 2022

Mr. Campbell reminded the Board that SEIs were due by April 15th.

Consent Agenda

The following items were approved with Mr. Nelson abstaining.

Consent Orders:

Catherine Pilkington (Technician Registration #29574)
Kristal Linn Crawford (Technician Registration #50320)
Michael Hoffler (Pharmacist License #26776)
Gary Dwight Justice (Pharmacist License #08431)
Lester Brandon McLellan (Pharmacist License #19029)
Alexander Shatalov (Pharmacist License #29102)
PostMeds, Inc. DBA Truepill (Pharmacy Permit #13413)

Reciprocity Candidates

License Number	First Name	Last Name	License Status	Licensed Date
31063	Bryan	Yourich	Active	2022-01-20
31060	Hassan	Ahmed	Active	2022-01-20
31062	Merlin	Paul	Active	2022-01-20
31061	Morgan	Jones	Active	2022-01-20
31065	Amy	Caraveo	Active	2022-01-27
31068	Kandice	Hodges	Active	2022-01-27
31067	Lance	Enfinger	Active	2022-01-27
31070	Meenakshi	Vadrevu	Active	2022-01-27
31069	Matthew	Shortell	Active	2022-01-27
31066	Ganesh	Chandran	Active	2022-01-27
31078	Katherine	Twomey	Active	2022-02-03
31079	Antoinette	Wallace	Active	2022-02-03
31075	Kevin	Harrison	Active	2022-02-03
31074	Susan	Dougherty	Active	2022-02-03
31080	Lih-Wern	Wang	Active	2022-02-03
31076	Susan	Kidd	Active	2022-02-03
31077	Jessalyn	Tackett	Active	2022-02-03
31090	Tsion	Tafesse	Active	2022-02-10
31001	Jenna	Reaves	Active	2022-02-10

31083	Kristle	Green	Active	2022-02-10
31084	Sarah	Malobabic	Active	2022-02-10
31085	Christine	Meaux	Active	2022-02-10
31089	David	Sugrue	Active	2022-02-10
31088	Penny	Scardulla	Active	2022-02-10
31087	Anupaben	Patel	Active	2022-02-10
31086	Anisha	Patel	Active	2022-02-10
31100	Omotayo	Salami	Active	2022-02-17
31099	Chelsey	Hanafin	Active	2022-02-17
31098	Eric	Garst	Active	2022-02-17
31096	James	Brooks	Active	2022-02-17
31101	Geoffrey	Zettel	Active	2022-02-17
31097	Joseph	D'Astoli	Active	2022-02-17
31105	Debbe	Escamillo	Active	2022-02-24
31107	Douglas	Healy	Active	2022-02-24
31111	Kayla	Pangburn	Active	2022-02-24
31073	Ashley	Temples	Active	2022-02-24
31106	Scott	Garland	Active	2022-02-24
31108	Lindsey	Kozlowski	Active	2022-02-24
31112	Xuan Quynh	Pham	Active	2022-02-24
31109	Juli	Moseley	Active	2022-02-24
31110	John	Muche	Active	2022-02-24

31120	John	Sears	Active	2022-03-03
31118	Shannon	Furbish	Active	2022-03-03
31122	April	Thompkins	Active	2022-03-03
31121	Vincent	Thai	Active	2022-03-03
31116	Nicole	Bachstein	Active	2022-03-03
31117	Austin	Bentley	Active	2022-03-03
31119	Nupoor	Kalke	Active	2022-03-03

CPP Candidates

License Number	First Name	Last Name	Licensed Date
700344	Thomas	Moscatelli	2022-01-21
700346	Raymond	Elliott	2022-02-01
700347	Anne	Rodino	2022-02-01
700345	Bianka	Patel	2022-02-01
700348	Regan	Porter	2022-02-09
700350	Caroline	McDaniel	2022-02-24
700351	Emily	Gwynn	2022-02-25
700352	Catherine	Nguyen	2022-02-28
700354	Morgan	Jones	2022-02-28
700353	Mattlyn	Tart	2022-02-28
700357	Rachelle	Kelley	2022-03-03

700356	Sara	Craven Brown	2022-03-03
700355	Jacob	Potts	2022-03-03

Increase in Pharmacist to Technicians Ratio

License Number	Process Type	Pharmacy Name	Complete Date
13866	PT Ratio Change 1:4	Drugco Discount	2022-01-19
11904	PT Ratio Change 1:3	Harris Teeter	2022-01-21
12240	PT Ratio Change 1:5	Walgreens	2022-01-21
8028	PT Ratio Change 1:5	Wal-Mart	2022-01-21
12466	PT Ratio Change 1:5	Walgreens	2022-01-21
12374	PT Ratio Change 1:4	Walgreens	2022-01-21
7949	PT Ratio Change 1:5	Wal-Mart	2022-01-21
12355	PT Ratio Change 1:5	Walgreens	2022-01-21
12447	PT Ratio Change 1:5	Walgreens	2022-01-21
12222	PT Ratio Change 1:5	Walgreens	2022-01-21
11862	PT Ratio Change 1:5	Wal-Mart	2022-01-21
12293	PT Ratio Change 1:5	Walgreens	2022-01-24
7944	PT Ratio Change 1:5	Walgreens	2022-01-24
10824	PT Ratio Change 1:4	CVS	2022-01-24
11972	PT Ratio Change 1:3	Harris Teeter	2022-01-24
12371	PT Ratio Change 1:5	Walgreens	2022-01-25
5099	PT Ratio Change 1:5	Moose Professional	2022-01-25

12273	PT Ratio Change 1:5	Walgreens	2022-01-26
9470	PT Ratio Change 1:4	Wal-Mart	2022-01-28
9147	PT Ratio Change 1:5	Wal-Mart	2022-01-30
12195	PT Ratio Change 1:5	Walgreens	2022-01-31
12453	PT Ratio Change 1:5	Walgreens	2022-02-01
8027	PT Ratio Change 1:4	Wal-Mart	2022-02-01
12526	PT Ratio Change 1:4	Wal-Mart	2022-02-01
12206	PT Ratio Change 1:5	Walgreens	2022-02-01
10021	PT Ratio Change 1:5	Wal-Mart	2022-02-02
12620	PT Ratio Change 1:4	Wal-Mart	2022-02-02
12422	PT Ratio Change 1:5	Walgreens	2022-02-02
12403	PT Ratio Change 1:5	Walgreens	2022-02-03
12331	PT Ratio Change 1:5	Walgreens	2022-02-08
10165	PT Ratio Change 1:4	CVS	2022-02-08
12433	PT Ratio Change 1:5	Walgreens	2022-02-08
7962	PT Ratio Change 1:5	Wal-Mart	2022-02-08
12404	PT Ratio Change 1:5	Walgreens	2022-02-08
12748	PT Ratio Change 1:5	Wal-Mart	2022-02-08
10729	PT Ratio Change 1:4	CVS	2022-02-09
12265	PT Ratio Change 1:5	Walgreens	2022-02-09
12494	PT Ratio Change 1:5	Walgreens	2022-02-09
12651	PT Ratio Change 1:5	Therapeutic Solutions	2022-02-14

10781	PT Ratio Change 1:4	CVS	2022-02-16
12420	PT Ratio Change 1:3	Walgreens	2022-02-16
11981	PT Ratio Change 1:5	Wal-Mart	2022-02-16
12889	PT Ratio Change 1:3	QuikMed	2022-02-17
7956	PT Ratio Change 1:5	Wal-Mart	2022-02-19
12207	PT Ratio Change 1:5	Walgreens	2022-02-21
10840	PT Ratio Change 1:5	CVS	2022-02-21
13585	PT Ratio Change 1:4	Walgreens	2022-02-21
12446	PT Ratio Change 1:5	Walgreens	2022-02-21
12281	PT Ratio Change 1:5	Walgreens	2022-02-22
13681	PT Ratio Change 1:5	Walgreens	2022-03-01
12329	PT Ratio Change 1:4	Walgreens	2022-03-01
7942	PT Ratio Change 1:5	Wal-Mart	2022-03-02
14147	PT Ratio Change 1:3	Blue Ridge Health - Haywood	2022-03-02
12021	PT Ratio Change 1:5	UNC Central OutPatient	2022-03-03
12287	PT Ratio Change 1:5	Walgreens	2022-03-04

President Mixon authorized Mr. Campbell to sign orders on his behalf. Mr. Campbell noted that after closed session, there would not be any more items on the agenda and meeting would be adjourned. On a motion from Dr. Duggins, seconded by Dr. Bowman, passed unanimously, the Board moved into closed session to discuss a possible summary suspension. Upon return to open session, President Mixon stated that the Board summarily suspended Technician Registration No. 55525 issued to Winter Carla Glenn. Dr. Bowman moved to adjourn. Ms. Corbin seconded. The motion passed with no dissenting votes.

William A. Mixon, President

Dr. Andy Bowman

Mischelle Corbin

Dr. Ashley Duggins

Wallace Nelson

Dr. Keith Vance